Raffaele Strippoli


Titolo Pubblicato in Anno
Definition and validation of serum biomarkers for optimal differentiation of hyperferritinaemic cytokine storm conditions in children: a retrospective cohort study THE LANCET. RHEUMATOLOGY 2021
Editorial: new approaches to tackle EMT and fibrosis: from epigenetics to nanotechnology FRONTIERS IN PHARMACOLOGY 2021
Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response JOURNAL OF HEPATOLOGY 2021
Autophagy and the lysosomal system in cancer CELLS 2021
Pleural mesothelial cells modulate the inflammatory/profibrotic response during SARS-CoV-2 infection FRONTIERS IN MOLECULAR BIOSCIENCES 2021
Molecular mechanisms and new therapeutic targets in epithelial to mesenchymal transition (EMT) and fibrosis FRONTIERS IN PHARMACOLOGY 2020
Novel quinoline compounds active in cancer cells through coupled DNA methyltransferase inhibition and degradation CANCERS 2020
Design of first-in-class dual EZH2/HDAC inhibitor: biochemical activity and biological evaluation in cancer cells ACS MEDICINAL CHEMISTRY LETTERS 2020
Caveolin1 and YAP drive mechanically induced mesothelial to mesenchymal transition and fibrosis CELL DEATH & DISEASE 2020
Nanomaterials for Autophagy-Related miRNA-34a Delivery in Cancer Treatment FRONTIERS IN PHARMACOLOGY 2020
Design and functional validation of a mutant variant of the lncRNA HOTAIR to counteract Snail function in Epithelial-to-Mesenchymal Transition CANCER RESEARCH 2020
Development of alkyl glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-mesenchymal transition in cancer cells EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 2019
Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells CLINICAL EPIGENETICS 2019
Sestrins at the Interface of ROS Control and Autophagy Regulation in Health and Disease OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2019
TGFβ impairs HNF1α functional activity in Epithelial-to-Mesenchymal Transition interfering with the recruitment of CBP/p300 acetyltransferases FRONTIERS IN PHARMACOLOGY 2019
Interplay between ROS and Autophagy in Cancer and Aging: From Molecular Mechanisms to Novel Therapeutic Approaches OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2019
YAP integrates the regulatory Snail/HNF4α circuitry controlling epithelial/hepatocyte differentiation CELL DEATH & DISEASE 2019
An Abl-FBP17 mechanosensing system couples local plasma membrane curvature and stress fiber remodeling during mechanoadaptation NATURE COMMUNICATIONS 2019
Nanomaterials as Inhibitors of Epithelial Mesenchymal Transition in Cancer Treatment CANCERS 2019
Erratum: Caveolin-1 Modulates Mechanotransduction Responses to Substrate Stiffness through Actin-Dependent Control of YAP (Cell Reports (2018) 25(6) (1622–1635.e6), (S2211124718316000) (10.1016/j.celrep.2018.10.024)) CELL REPORTS 2019


  • LS1_9
  • LS2_3
  • LS3
  • LS3_4
  • LS3_5
  • LS3_7
  • LS4_12
  • LS6
  • LS6_1
  • LS6_3


  • Life-science technologies & biotechnologies

Interessi di ricerca

I have a background in innate immunity and in cellular/molecular biology. I am interested in molecular mechanisms controlling the induction/reversal of Epithelial to Mesenchymal Transition (EMT) and fibrosis. In particular, I focused my investigation in the role of both extracellular mediators and biomechanical/biophisical cues in the induction of cellular plasticity and signalling pathways implicated. I recently studied the interplay between Caveolin1, a plasma membrane mechanotransducer,  and YAP/TAZ, effectors of a main biomechanical pathway, in the induction of peritoneal fibrosis.

I am presently involved in research projects related to biomechanical regulation of EMT and to the control of EMT induction/reversal by epigenetic factors. Moreover, I am interested in the role of infections in the modulation of epithelial cell plasticity.


cell signalling
fibrosis mesothelial cells mechanotransduction YAP Caveolin1
Liver fibrosis
toll like receptors
Extracellular Signal-Regulated MAP Kinases
transforming growth factor beta (TGFβ)
HDAC inhibitors
pneumonia: Sars-Cov-2

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma